Publication at Faculty of Medicine in Hradec Králové |
2023
Abstract
Metastatic renal cancer is serious disease with serious prognosis. The management covers surgery od primary tumor, eventually on metastasis.
Lymphadenectomy has no therapeutical impact; it is useful for staging only. Monoclonal antibody, tyrosinkinase inhibitors, mammalian targets of rapamycin (mTOR) and cytokines can be used for oncological management.
The complex therapy needs multidisciplinary cooperation and well-informed patient.